Antonio Grimaldi: The Test for the Analysis of the BRCA1 and BRCA2 Genes is Available
Antonio Grimaldi, Director of U.O.C. Oncology at AORN San Pio, shared on LinkedIn:
“AORN San Pio di Benevento, the test for the analysis of the BRCA1 and BRCA2 genes is available
Prevention and Health are constant objectives of the Director General of AORN SAN PIO Maria Morgante increasingly close to citizens in early diagnosis and cancer prevention.
From 23 June 2025 it is possible to carry out the test for mutations in the BRCA1 and BRCA2 genes at the UOSD ‘Medical Genetics’ and thus assess the individual risk of developing tumors associated with these.
Being able to perform these tests within the AORN represents a significant step in offering personalized care to patients with breast, ovarian, prostate and pancreatic cancers.
“The objective of the strategic direction is to provide quality health services to citizens-users – highlights the Director General Maria Morgante-
The introduction of this test represents a step forward, useful for aligning the diagnosis and treatment services of cancer with those already provided by the AORN San Pio. In this way, it will be possible to consolidate the already very advanced level of these specialties and further improve patient care.”
More posts featuring Antonio Grimaldi.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023